Gaurav Shah sold $20k of RCKT
CEO at ROCKET PHARMACEUTICALS, INC.. 5,990 shares at an average of $3.34, traded Feb 18, 2026, filed Feb 20, 2026.
Score components
- +25RoleCEO
- 0Trade size$20k at market
- 0Share of holdings soldSold 0.6% of holdings
- +15Cluster3 insiders selling within 14 days
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m +9.5%, 3m -21.7%, 6m -7.1%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001140361-26-006326, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Feb 18, 2026 | SOpen-market sale Common Stock | -5,990 | $3.34 | $20k | 1,046,055 | Feb 20, 2026 |
Related signals
Other insiders at ROCKET PHARMACEUTICALS, INC. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 33Weak | RCKTsell ROCKET PHARMACEUTICALS, INC. | Martin Wilson General Counsel | $256k 75,364 shares | -11% | |
| 40Moderate | ROCKET PHARMACEUTICALS, INC. | Gaurav Shah CEO | $7,753 2,293 shares | -0% | |
| 30Weak | ROCKET PHARMACEUTICALS, INC. | Martin Wilson General Counsel | $2,133 631 shares | -0% | |
| 30Weak | ROCKET PHARMACEUTICALS, INC. | Martin Wilson General Counsel | $12k 3,493 shares | -1% | |
| 40Moderate | ROCKET PHARMACEUTICALS, INC. | Gaurav Shah CEO | $9,592 2,837 shares | -0% | |
| 30Weak | ROCKET PHARMACEUTICALS, INC. | Sarbani Chaudhuri See Remarks | $16k 4,701 shares | -2% | |
| 46Moderate | ROCKET PHARMACEUTICALS, INC. | Christopher James Stevens Chief Operating Officer | $128k 36,658 shares | -7% | |
| 36Weak | ROCKET PHARMACEUTICALS, INC. | Gaurav Shah CEO | $172k 55,684 shares | -5% | |
| 30Weak | ROCKET PHARMACEUTICALS, INC. | John Militello See Remarks | $1,157 384 shares | -0% | |
| 30Weak | ROCKET PHARMACEUTICALS, INC. | Martin Wilson General Counsel | $1,995 662 shares | -0% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.